0000000000610227

AUTHOR

Henk W. Reesink

showing 4 related works from this author

Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study

2018

PubMed: 29599078

0301 basic medicineBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences.HBsAgPediatricsDelphi TechniqueInfectious Disease TransmissionCHRONIC HBV INFECTION ; NATURAL-HISTORY ; FOLLOW-UP ; HBSAG ; CARRIERS ; AGE ; COUNTRIES ; DISEASE ; ANTIGEN ; COHORTddc:616.07Global Healthmedicine.disease_causeDISEASE0302 clinical medicinePrevalenceHBVChildddc:616Antiviral Agents/therapeutic useeducation.field_of_studyBIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti.Chronic/drug therapy/epidemiology/prevention & control/transmissionGastroenterologyHepatitis B Surface Antigens/bloodHepatitis BCARRIERSHepatitis B10219 Clinic for Gastroenterology and HepatologyChild Preschool030211 gastroenterology & hepatologyViral hepatitisViral loadCOUNTRIESAdultmedicine.medical_specialtyHepatitis B vaccineANTIGENPopulation610 Medicine & healthAntiviral AgentsMass VaccinationHepatology; Gastroenterology03 medical and health sciencesHepatitis B ChronicHBSAGAGESDG 3 - Good Health and Well-beingmedicineHumansCOHORT2715 GastroenterologyPreschooleducationDisease burdenHepatitis B virusHepatitis B Surface AntigensHepatologybusiness.industryViral VaccinesNATURAL-HISTORYmedicine.diseaseInfectious Disease Transmission VerticalCHRONIC HBV INFECTIONVertical/prevention & control030104 developmental biology2721 HepatologyHuman medicineFOLLOW-UPbusiness
researchProduct

Global prevalence and genotype distribution of hepatitis C virus infection in 2015:a modelling study

2017

WOS: 000426979400014

Viremia/epidemiologyPopulation ageingmedicine.medical_specialtyCIENCIAS MÉDICAS Y DE LA SALUDDelphi TechniqueGenotypeVoxilaprevirGenotype Global Health Hepatitis C Eradication Modelling studyMedicina Clínicaddc:616.07Global HealthBioinformatics03 medical and health sciences0302 clinical medicineCost of IllnessEpidemiologyJournal ArticlemedicineGlobal healthPrevalenceHumansViremia030212 general & internal medicineDisease EradicationDisease burdenddc:616HepatologyHepatitis C Chronic/epidemiologybusiness.industryGastroenterologyHepatitis CGlecaprevirHepatitis C Chronicmedicine.diseaseViremia/epidemiology/geneticsPibrentasvirGlobal Health/statistics & numerical dataHCVHEPATITIS C030211 gastroenterology & hepatologyMedicina Critica y de EmergenciaHuman medicinebusinessChronic/epidemiology/genetics/prevention & controlDemography
researchProduct

Failure of acyclovir to enhance the antiviral effect of α lymphoblastoid interferon on HBe-seroconversion in chronic hepatitis B

1992

Serum HBeAg levels and HBe-seroconversion were investigated in patients with chronic HBeAg-positive hepatitis who were randomized to receive either alpha lymphoblastoid interferon (5 megaunits subcutaneously daily for 16 weeks) plus acyclovir (2 g intravenously daily during weeks 1 and 2 and weeks 9 and 10) (n = 49) or no treatment (n = 48). HBeAg levels in serial dilutions of patient serum were assessed quantitatively by radioimmunoassay and compared with the values found for negative control serum. One year after the start of therapy 44 treated patients and 43 control patients were available for follow-up. A complete response (HBe-seroconversion) occurred in 11 treated patients (25%) and …

HepatitisChemotherapymedicine.medical_specialtyHepatologyCombination therapybusiness.industrymedicine.medical_treatmentvirus diseasesAlpha interferonmedicine.diseaseGastroenterologydigestive system diseasesHBeAgInternal medicineImmunologymedicineAciclovirSeroconversionbusinessInterferon alfamedicine.drugJournal of Hepatology
researchProduct

Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling…

2017

Background Hepatitis C virus (HCV) is a leading cause of liver-related morbidity and mortality worldwide. In the European Union (EU), treatment and cure of HCV with direct-acting antiviral therapies began in 2014. WHO targets are to achieve a 65% reduction in liver-related deaths, a 90% reduction of new viral hepatitis infections, and 90% of patients with viral hepatitis infections being diagnosed by 2030. This study assessed the prevalence of HCV in the EU and the level of intervention required to achieve WHO targets for HCV elimination. Methods We populated country Markov models for the 28 EU countries through a literature search of PubMed and Embase between Jan 1, 2000, and March 31, 201…

Pediatricsddc:616.07medicine.disease_cause0302 clinical medicineCost of IllnessEpidemiologyPrevalenceEPIDEMIOLOGY030212 general & internal medicineSettore SECS-P/01 - Economia PoliticaCIRRHOSISmedia_commonddc:616Antiviral Agents/therapeutic useeducation.field_of_studyINJECT DRUGSGastroenterologyHCV INFECTIONvirus diseasesHepatitis CEmigration and ImmigrationDISEASE BURDENHepatitis CMarkov ChainsEmigration and Immigration/statistics & numerical data030211 gastroenterology & hepatologyViral hepatitisModelling ; Eradication ; European Union ; Hepatitis C ; prevalenceCOUNTRIESmedicine.medical_specialtyHepatitis C virusPopulationUNITED-STATESWorld Health OrganizationAntiviral Agents03 medical and health sciencesSDG 3 - Good Health and Well-beingPEOPLEInternal medicineIntervention (counseling)medicineJournal Articlemedia_common.cataloged_instanceHumansEuropean UnionViremiaEuropean unionDisease EradicationeducationHepatitis C/diagnosis/drug therapy/epidemiology/prevention & controlHepatologybusiness.industryViremia/diagnosis/drug therapy/epidemiology/prevention & controlHepatologymedicine.diseaseVirologyPREVENTIONdigestive system diseasesHuman medicineVIRAL-HEPATITISbusinessLancet Gastroenterology & Hepatology
researchProduct